Daiichi Sankyo | pharmaphorum

Sunday 24 November 2024

Channels

Content type

Categories

Categories

Sort by

Order

Daiichi Sankyo

News

AZ, Daiichi’s TROP2 drug hits the mark in lung cancer

AZ, Daiichi’s TROP2 drug hits the mark in lung cancer

AstraZeneca and partner Daiichi Sankyo have their first phase 3 data for TROP2-targeting antibody-drug conjugate (ADC) datopotamab deruxtecan (Dato-DXd) – in lung cancer –

Oncology

Oncology 2023

Oncology 2023

Oncology 2023 features interviews, analysis, and commentary from pharmaphorum, industry leaders, and more

News

ASCO: Enhertu data sets up tumour-agnostic label bid

ASCO: Enhertu data sets up tumour-agnostic label bid

AstraZeneca and Daiichi Sankyo’s Enhertu is already gathering momentum as a treatment for HER2-positive and HER2-low breast, gastric, and lung cancer, but new data could b

News

Japanese pharmas sign up to use new AI supercomputer

Japanese pharmas sign up to use new AI supercomputer

Mitsui, NVIDIA's Tokyo-1 supercomputer, aims to turbocharge Japan’s use of AI in drug discovery

News

Tug of war

Esperion and Daiichi Sankyo square up on Nexletol milestone

Companies can't see eye to eye on the recently reported data from the CLEAR outcomes study.

News

Enhertu

Daiichi Sankyo wins round in Enhertu patent dispute

US PTO has agreed to take another look at whether Seagen's '039 patent is valid.